Zamtocabtagene Autoleucel — Drug Intelligence | 4 EU Trials

Filter these 4 trials by condition, phase, country and more.

4 Registered trials

2 Recruiting

1 Completed trials

1 Sponsors

15 Countries

Phase II

Phase I/II

Phase II: 3 Phase I/II: 1

Oversight events:

1 serious breach 10 unexpected events 1 corrective measure across 2 trials

Indications tested

4 total

DALY II USA/MB-CART2019.1 for DLBCL Pending

2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms Recruiting

2023-506348-17-00 Phase II 4 countries Miltenyi Biomedicine GmbH
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting

2022-501648-14-00 Phase I/II 1 country Miltenyi Biomedicine GmbH
DALY 2-EU Ended

2023-506270-13-00 Phase II 15 countries Miltenyi Biomedicine GmbH

Showing 1–4 of 4 trials